Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection

(2022) Chansavath Phetsouphanh et al.   NATURE IMMUNOLOGY

SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13

(2022) Cameron B. Morrison et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis

(2021) Ana Macedo et al.   ANNALS OF EPIDEMIOLOGY

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

(2021) Ivan O. Rosas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

(2021)   NEW ENGLAND JOURNAL OF MEDICINE

CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes

(2021) Dave J. Baker et al.   Genome Medicine

IL-33 in COVID-19: friend or foe?

(2021) Yuejin Liang et al.   Cellular & Molecular Immunology

N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection

(2021) Dandan Shan et al.   Nature Communications

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

(2021) Jennifer D. Hamilton et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels

(2021) et al.   ANNALS OF INTERNAL MEDICINE

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab

(2021) Benjamin Ungar et al.   Journal of Allergy and Clinical Immunology-In Practice

Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies

(2021) Bob Geng et al.   Journal of Allergy and Clinical Immunology-In Practice

COVID-19 Post-acute Sequelae Among Adults: 12 Month Mortality Risk

(2021) Arch G. Mainous et al.   Frontiers in Medicine

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Longitudinal analyses reveal immunological misfiring in severe COVID-19

(2020) Carolina Lucas et al.   NATURE

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

(2020) Andre C. Kalil et al.   NEW ENGLAND JOURNAL OF MEDICINE

A review of dupilumab in the treatment of atopic diseases

(2019) Quinn Thibodeaux et al.   Human Vaccines & Immunotherapeutics

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

(2016) Sally Wenzel et al.   LANCET

Monocyte Chemoattractant Protein-1 (MCP-1): An Overview

(2009) Satish L. Deshmane et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH